References

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Pharmacoeconomic Review Report: tiotropium bromide monohydrate (Spiriva Respimat) for inhalation [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Jul.

Cover of Pharmacoeconomic Review Report: tiotropium bromide monohydrate (Spiriva Respimat) for inhalation

Pharmacoeconomic Review Report: tiotropium bromide monohydrate (Spiriva Respimat) for inhalation [Internet].

Show details

Contents

< PrevNext >

References

1.: ^PrSpiriva® Respimat® inhalation solution, 2.5 mcg tiotropium per actuation (as tiotropium bromide monohydrate) bronchodilator [product monograph]. Burlington (ON): Boehringer Ingelheim (Canada) Ltd.; 2015 Feb 6.
2.: Pharmacoeconomic evaluation. In: CDR submission: Spiriva® Respimat® (tiotropium bromide), 2.5 µg solution for inhalation. Company: Boehringer Ingelheim [CONFIDENTIAL manufacturer’s submission]. Burlington (ON): Boehringer Ingelheim (Canada) Ltd.; 2014 Dec.
3.: van Noord JA, Cornelissen PJ, Aumann JL, Platz J, Mueller A, Fogarty C. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Respir Med. 2009 Jan;103(1):22–9. [PubMed: 19022642]
4.: Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, et al Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013 Oct 17;369(16):1491–501. [PubMed: 23992515]
5.: Wise RA, Anzueto A, Calverley P, Dahl R, Dusser D, Pledger G, et al The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale. Respir Res [Internet]. 2013 [cited 2015 Feb 18];14:40. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3621103 [PMC free article: PMC3621103] [PubMed: 23547660]
6.: Wise RA. Tiotropium and the risk of death in COPD. N Engl J Med. 2014 Jan 30;370(5):482. [PubMed: 24476441]
7.: Bateman E, Singh D, Smith D, Disse B, Towse L, Massey D, et al Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulmon Dis [Internet]. 2010 [cited 2015 Feb 18];5:197–208. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921687 [PMC free article: PMC2921687] [PubMed: 20714373]
8.: Dong YH, Lin HH, Shau WY, Wu YC, Chang CH, Lai MS. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax. 2013 Jan;68(1):48–56. [PubMed: 23042705]
9.: Oba Y, Lone NA. Comparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regression. Ther Adv Respir Dis. 2015 Feb;9(1):3–15. [PubMed: 25586493]
10.: O’Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk DD, Balter M, et al Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J [Internet]. 2007 Sep [cited 2015 Apr 21];14 Suppl B:5B–32B. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806792 [PMC free article: PMC2806792] [PubMed: 17885691]
11.: Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: updated 2015 [Internet]. London (UK): GOLD; 2015. [cited 2015 Apr 14]. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Apr2.pdf
12.: Common Drug Review. CDEC final recommendation. Indacaterol/glycopyrronium (Ultibro Breezhaler - Norvartis Pharmaceuticals Canada Inc.). Indication: chronic obstructive pulmonary disease [Internet]. Ottawa: CADTH; 2014 Dec 19. [cited 2015 Apr 20]. Available from: https://www.cadth.ca/media/cdr/complete/cdr_complete_SR0369_Ultibro%20Breezhaler_Jan30_2015.pdf
13.: Common Drug Review. CDEC final recommendation. Umeclidinum bromide/vilanterol trifenatate (Anoro Ellipta - GlaxoSmithKline Inc.). Indication: chronic obstructive pulmonary disease [Internet]. Ottawa: CADTH; 2015 Jan 15. [cited 2015 Apr 20]. Available from: https://www.cadth.ca/media/cdr/complete/cdr_complete_SR0371_Anoro_Ellipta_Jan-23-15.pdf

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK535471

Contents

< PrevNext >

PubReader
Print View
Cite this Page
Pharmacoeconomic Review Report: tiotropium bromide monohydrate (Spiriva Respimat) for inhalation [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Jul. References.
PDF version of this title (923K)